Showing 6791-6800 of 7742 results for "".
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescentshttps://practicaldermatology.com/news/dupixent-improves-moderate-to-severe-atopic-dermatitis-in-adolescents/2457764/DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with DUPIXENT as monotherapy significantly improved measures of overall disease severity, skin c
- National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Awardhttps://practicaldermatology.com/news/national-psoriasis-foundation-honors-dr-jerry-bagel-with-excellence-in-leadership-award/2457766/Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence in Leadership Award from the National Psoriasis Foundation (NPF) next month. For more th
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- Valeant is Becoming Bausch Health Companies, Inc.https://practicaldermatology.com/news/valeant-is-becoming-bausch-health-companies-inc/2457770/Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on th
- Skin Cancer Foundation Hits the Roadhttps://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road/2457771/The Skin Cancer Foundation kicks off the second year of its mobile education and screeing program called Destination: Healthy Skin. Starting Tuesday, May 15, in New York City, the tour will stop in 15 cities ov
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness